What we do Marksans Pharma Limited researches, manufactures, markets, and sells pharmaceutical formulations, focusing on generics and OTC products across global regulated markets. |
Founded in 1,982 |
Market share Among top Indian pharma firms in UK and leading store brand manufacturer in US OTC market; strong presence in Australia and New Zealand. |
Problem solved Provides affordable, high-quality generic and OTC pharmaceuticals addressing global healthcare needs. |
Top clients or who we serve Serves retailers, healthcare providers, and consumers in regulated markets including US, UK, Australia, and Middle East; B2B and B2C focus. |
Key management Mark Saldanha (Founder, Chairman & Managing Director) with 30+ years in pharma; skilled leadership in global manufacturing, R&D, and marketing. |
Our journey and innovations Founded in 1982, rebranded in 2005, expanded via acquisitions in US, UK, Australia; developed strong R&D centers and approved 100+ ANDAs. |
Where we operate Operations in US, UK, Europe, Australia, New Zealand, Middle East, and India with manufacturing and R&D facilities in India, US, UK. |
Top products or what we offer Wide portfolio including tablets, capsules, soft gels, liquids, ointments, OTC, and Rx generics across diverse therapeutic segments. |
Top brands Includes store brand OTC products and private label generics; leading positions in cough & cold, pain management, and allergy categories. |
Raw materials needed Pharmaceutical-grade chemical ingredients, excipients, and packaging materials sourced globally for manufacturing formulations. |
Raw materials supplier Supplied primarily by approved global raw material vendors ensuring compliance with regulatory standards. |
Recurring vs cyclical contribution Revenue largely recurring from long-term contracts with retailers and steady product sales; mitigates cyclicality through diverse geographic presence. |
Our industry position Strong market share in OTC generics in US and UK; among top Indian pharma exporters with regulatory accreditations from USFDA, MHRA, TGA. |
Financial highlights FY25 consolidated revenue ₹2622.85 crore; PAT ₹380.58 crore; consistent EBITDA margins ~20%; strong cash generation and balance sheet. |
Geographical revenue split FY25 revenue: US & North America 47%, UK & Europe 39%, Australia & New Zealand 9.5%, Rest of World 4% approximately. |
Order book - |
Whats driving growth Growth driven by expanding OTC portfolio, new product launches, increased capacity, strategic acquisitions, and favorable market demand in US and Europe. |
Our future plans Plan to double manufacturing capacity in India, expand US OTC business, enhance product pipeline, and pursue acquisitions in Europe and Canada. |
Our green promise Committed to sustainability via recyclable packaging, reducing plastic usage, energy efficiency, community health initiatives, and responsible governance. |
Our people and values Over 2,000 employees, fostering talent development, diversity, ethical conduct, and employee empowerment across global locations. |
Key challenges ahead Managing pricing pressures, regulatory compliance, raw material cost volatility, and competition in regulated markets. |
Interesting facts Operates one of Asia's largest pharma units; sustained >5 years of cash-positive operations; significant growth through inorganic acquisitions. |
Risks and strategy Mitigates risks via diversified geographies, robust R&D, compliance systems; strategic focus on stable OTC segments and controlled exposure in emerging markets. |
